AEON Biopharma (AEON) Competitors

Artelo Biosciences (NASDAQ:ARTL) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership.

Which has more volatility & risk, ARTL or AEON?

Artelo Biosciences has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Is ARTL or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-104.59%	-94.06%
AEON Biopharma	N/A	N/A	-994.63%

Does the media prefer ARTL or AEON?

In the previous week, AEON Biopharma had 3 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for AEON Biopharma and 1 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.44 beat AEON Biopharma's score of 0.15 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Neutral
AEON Biopharma	Neutral

Does the MarketBeat Community prefer ARTL or AEON?

Artelo Biosciences received 40 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 77.42% of users gave Artelo Biosciences an outperform vote.

Company	Underperform	Outperform
Artelo Biosciences	Outperform Votes 48 77.42%	Underperform Votes 14 22.58%
AEON Biopharma	Outperform Votes 8 100.00%	Underperform Votes No Votes

Do insiders & institutionals believe in ARTL or AEON?

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 0.8% of Artelo Biosciences shares are held by company insiders. Comparatively, 7.0% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend ARTL or AEON?

Artelo Biosciences currently has a consensus target price of $5.50, indicating a potential upside of 485.11%. AEON Biopharma has a consensus target price of $360.00, indicating a potential upside of 60,201.51%. Given AEON Biopharma's higher probable upside, analysts plainly believe AEON Biopharma is more favorable than Artelo Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50
AEON Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, ARTL or AEON?

Artelo Biosciences is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$9.29M	-$3.05	-0.31
AEON Biopharma	N/A	N/A	-$36.63M	$67.78	0.01

Summary

Artelo Biosciences and AEON Biopharma tied by winning 8 of the 16 factors compared between the two stocks.